ELTX Stock Forecast & Price Target

Elicio Therapeutics is supported by compelling mechanistic and clinical evidence that its AMP platform can generate strong, durable mKRAS-specific immune responses, with Ph2 7P data showing a 99% T cell response rate, 145x average fold-change, and meaningful antigen spreading across a broader, harder-to-immunize population. The investment case is further strengthened by Ph1 correlations linking stronger immune responses to better outcomes, including median RFS not reached at 24+ months versus 3.0 months in weak responders and median OS of 28.9 months versus 16.0 months, suggesting the biology translates into clinically relevant benefit. Financially, the company’s outlook benefits from reduced development risk in adjuvant PDAC, a higher estimated probability of approval at 65% versus 50%, and a raised peak market penetration assumption of 50%, while the broader pipeline in CRC, mBRAF, and mTP53 adds long-term platform optionality.

Elicio Therapeutics is a high-risk, pre-revenue biotech whose value depends heavily on a single lead asset, ELI-002 7P, which still faces clinical, regulatory, and commercialization uncertainty despite encouraging biomarker signals. While the 4.9 mg Phase 1a dose showed a 71% decline in ctDNA or serum tumor markers and a clean safety profile with no dose-limiting toxicities, the small sample sizes and maturing data leave open the possibility that efficacy may not translate into pivotal success or regulatory approval. The company’s cash runway extends through 4Q26, but the need for additional capital, possible dilution, and dependence on mostly pending patents and MIT-controlled intellectual property create material fundamental downside risk.